drugset / Trial / NCT00366782

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

NCT00366782 ↗

RandomizedParallel-groupTriple-blindPrevention

Summary

Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease. The purpose of this study is to test the safety of and immune response to a new HPIV vaccine in healthy infants, children, and adults.

Timeline

Start
2007-03
Primary completion
2011-02
Completion
2011-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject rB/HPIV3 Vaccine 100000 unknown Intranasal
Subject rB/HPIV3 Vaccine 1e+06 unknown Intranasal